167 related articles for article (PubMed ID: 23557396)
1. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.
Bonella F; Ohshimo S; Miaotian C; Griese M; Guzman J; Costabel U
Orphanet J Rare Dis; 2013 Apr; 8():53. PubMed ID: 23557396
[TBL] [Abstract][Full Text] [Related]
2. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.
Bonella F; Long X; Ohshimo S; Horimasu Y; Griese M; Guzman J; Kohno N; Costabel U
Orphanet J Rare Dis; 2016 Apr; 11():48. PubMed ID: 27108412
[TBL] [Abstract][Full Text] [Related]
3. [The clinical significance of the levels of serum KL-6 mucin and interleukin-13 in pulmonary alveolar proteinosis].
Zhou J; Xiao Y; Ding J; Zhou K; Zhou Z; Cai H
Zhonghua Jie He He Hu Xi Za Zhi; 2015 Feb; 38(2):110-4. PubMed ID: 25908420
[TBL] [Abstract][Full Text] [Related]
4. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.
Bonella F; Long X; He X; Ohshimo S; Griese M; Guzman J; Costabel U
Respirology; 2017 Oct; 22(7):1371-1378. PubMed ID: 28569052
[TBL] [Abstract][Full Text] [Related]
5. Serum KL-6 in pulmonary alveolar proteinosis: China compared historically with Germany and Japan.
Guo WL; Zhou ZQ; Chen L; Su ZQ; Zhong CH; Chen Y; Li SY
J Thorac Dis; 2017 Feb; 9(2):287-295. PubMed ID: 28275476
[TBL] [Abstract][Full Text] [Related]
6. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis.
Takahashi T; Munakata M; Suzuki I; Kawakami Y
Am J Respir Crit Care Med; 1998 Oct; 158(4):1294-8. PubMed ID: 9769294
[TBL] [Abstract][Full Text] [Related]
7. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome.
Kida Y; Ohshimo S; Ota K; Tamura T; Otani T; Une K; Sadamori T; Iwasaki Y; Bonella F; Hattori N; Hirohashi N; Guzman J; Costabel U; Kohno N; Tanigawa K
Orphanet J Rare Dis; 2012 Dec; 7():99. PubMed ID: 23244165
[TBL] [Abstract][Full Text] [Related]
8. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
[TBL] [Abstract][Full Text] [Related]
9. Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis.
Lin FC; Chen YC; Chang SC
Mayo Clin Proc; 2008 Dec; 83(12):1344-9. PubMed ID: 19046553
[TBL] [Abstract][Full Text] [Related]
10. Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis.
Nakajima M; Manabe T; Niki Y; Matsushima T
Thorax; 1998 Sep; 53(9):809-11. PubMed ID: 10319067
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
[TBL] [Abstract][Full Text] [Related]
13. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary alveolar proteinosis during a 30-year observation. Diagnosis and treatment.
Fijołek J; Wiatr E; Radzikowska E; Bestry I; Langfort R; Polubiec-Kownacka M; Prokopowicz J; Roszkowski-Śliż K
Pneumonol Alergol Pol; 2014; 82(3):206-17. PubMed ID: 24793148
[TBL] [Abstract][Full Text] [Related]
15. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
[TBL] [Abstract][Full Text] [Related]
16. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
17. A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis.
Tokura S; Akira M; Okuma T; Tazawa R; Arai T; Sugimoto C; Matsumuro A; Hirose M; Takada T; Nakata K; Ishii H; Kasahara Y; Hojo M; Ohkouchi S; Tsuchihashi Y; Yokoba M; Eda R; Nakayama H; Nei T; Morimoto K; Nasuhara Y; Ebina M; Ichiwata T; Tatsumi K; Yamaguchi E; Inoue Y
Ann Am Thorac Soc; 2017 Sep; 14(9):1403-1411. PubMed ID: 28489417
[TBL] [Abstract][Full Text] [Related]
18. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
19. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
20. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.
Ohshimo S; Ishikawa N; Horimasu Y; Hattori N; Hirohashi N; Tanigawa K; Kohno N; Bonella F; Guzman J; Costabel U
Respir Med; 2014 Jul; 108(7):1031-9. PubMed ID: 24835074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
